NCT07414784CompletedPhase 1
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
A Phase 1 Drug-Drug Interaction Study of ABBV-295, Levonorgestrel, and Ethinyl Estradiol in Healthy Adult Female Subjects With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 11 Feb 2026
- Start date
- 11 Feb 2026
- Primary completion date
- 4 Aug 2026
- Lead sponsor
- AbbVie
- Diseases
- Obesity
- NCT number
- NCT07414784
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- From 11 Feb 2026 to the primary completion date, 4 Aug 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
- Participant has taken a medication for the purpose of treating obesity or has been enrolled in an obesity trial within 90 days prior to study treatment administration.
Lab values
- HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
Who the study is looking for
- BMI ≥ 25.0 to ≤ 35.0 kg/m2 after rounding to the tenths decimal at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters)
- A female who is not pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 60 days after the last dose of study treatment.
Age in the registry: 18 years to 65 years · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CenExel Act- Anaheim Clinical Trials /ID# 281863 Coordinator of this site? Confirm its status | Anaheim | United States | Unknown status |
| Acpru /Id# 280538 Coordinator of this site? Confirm its status | Grayslake | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.